AI Portfolio Summary
In 2025 Q4, Soleus Capital Management, L.P. maintained a portfolio of 120 distinct positions. The most significant new addition to the portfolio was DEXCOM INC, which now represents 3.18% of the total fund value. They heavily accumulated shares in SPDR SERIES TRUST, increasing their position by 152.2%. Conversely, Soleus Capital Management, L.P. completely exited their position in ELEVANCE HEALTH INC .
Total Positions
120
Quarter
2025 Q4
Top Holding
XBI (13.0%)
Top 10 Concentration
51.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 120
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 13.04% | 5.80% |
#1
3
Prev: #4
|
7.5 | 1,750,000 | 152.2% |
P
S
|
2,900,000 | $353,597,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 8.56% | 9.05% |
#2
1
Prev: #1
|
3.4 | -77,772 | -7.6% |
P
S
|
941,059 | $232,008,686 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
CELCUITY INC
|
Healthcare | 6.65% | 2.93% |
#3
6
Prev: #9
|
4.8 | 629,398 | 53.4% |
P
S
|
1,808,258 | $180,355,653 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NVCR
NOVOCURE LTD
|
Healthcare | 4.07% | 6.27% |
#4
1
Prev: #3
|
1.7 | -1,114,207 | -11.6% |
P
S
|
8,530,665 | $110,301,498 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 3.95% | 2.29% |
#5
11
Prev: #16
|
1.8 | -496,200 | -57.8% |
P
S
|
362,966 | $106,980,599 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TGTX
TG THERAPEUTICS...
|
Healthcare | 3.45% | 6.99% |
#6
4
Prev: #2
|
1.4 | -705,419 | -18.3% |
P
S
|
3,139,312 | $93,582,891 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DXCM
DEXCOM INC
|
Healthcare | 3.18% | — |
#7
Prev: #—
|
3.3 | 1,297,094 | no change |
NEW
|
1,297,094 | $86,088,129 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 2.89% | 2.43% |
#8
6
Prev: #14
|
3.3 | 429,696 | 48.3% |
P
S
|
1,320,000 | $78,447,600 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GMED
GLOBUS MED INC
|
Healthcare | 2.86% | 0.51% |
#9
37
Prev: #46
|
3.4 | 711,000 | 404.0% |
P
S
|
887,000 | $77,443,970 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBNX
BETA BIONICS IN...
|
Healthcare | 2.85% | 3.87% |
#10
4
Prev: #6
|
1.2 | -1,335,593 | -34.5% |
P
S
|
2,534,565 | $77,228,196 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FOLD
AMICUS THERAPEU...
|
Healthcare | 2.74% | 1.86% |
#11
6
Prev: #17
|
3.1 | 517,284 | 11.0% |
P
S
|
5,207,284 | $74,151,724 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TWST
TWIST BIOSCIENC...
|
Healthcare | 2.18% | 2.64% |
#12
1
Prev: #11
|
0.9 | -4,432 | -0.2% |
P
S
|
1,861,802 | $59,056,359 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORGO
ORGANOGENESIS H...
|
Healthcare | 1.91% | 2.58% |
#13
Prev: #13
|
0.8 | -2,145,748 | -17.7% |
P
S
|
9,985,951 | $51,727,226 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 1.74% | 1.56% |
#14
7
Prev: #21
|
2.7 | 235,000 | 11.7% |
P
S
|
2,247,110 | $47,211,781 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 1.67% | 0.55% |
#15
28
Prev: #43
|
3.0 | 424,918 | 285.8% |
P
S
|
573,614 | $45,309,770 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PODD
INSULET CORP
|
Healthcare | 1.57% | — |
#16
Prev: #—
|
2.6 | 150,000 | no change |
NEW
|
150,000 | $42,636,000 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NPCE
NEUROPACE INC
|
Healthcare | 1.54% | 1.54% |
#17
6
Prev: #23
|
0.6 | -254,749 | -8.6% |
P
S
|
2,703,208 | $41,737,532 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXGN
AXOGEN INC
|
Healthcare | 1.46% | 1.55% |
#18
4
Prev: #22
|
0.7 | -519,698 | -30.1% |
P
S
|
1,206,855 | $39,500,364 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANIP
ANI PHARMACEUTI...
|
Healthcare | 1.42% | 1.57% |
#19
1
Prev: #20
|
2.7 | 146,000 | 42.9% |
P
S
|
486,243 | $38,384,022 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.36% | — |
#20
Prev: #—
|
2.5 | 1,322,364 | no change |
NEW
|
1,322,364 | $36,999,745 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LIVN
LIVANOVA PLC
|
Healthcare | 1.29% | — |
#21
Prev: #—
|
2.5 | 567,500 | no change |
NEW
|
567,500 | $34,918,275 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GSK
GSK PLC
|
Healthcare | 1.16% | 0.48% |
#22
25
Prev: #47
|
2.8 | 419,000 | 190.5% |
P
S
|
639,000 | $31,336,560 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GERN
GERON CORP
|
Healthcare | 1.13% | 1.19% |
#23
2
Prev: #25
|
2.6 | 6,000,000 | 34.7% |
P
S
|
23,290,000 | $30,742,800 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 1.08% | 3.17% |
#24
17
Prev: #7
|
0.6 | -90,000 | -60.0% |
P
S
|
60,000 | $29,235,000 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 1.04% | — |
#25
Prev: #—
|
2.4 | 1,110,000 | no change |
NEW
|
1,110,000 | $28,216,200 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELV
ELEVANCE HEALTH...
|
Healthcare | 0.00% | 4.22% |
Sold All 😨
(Was: #5) |
0.3 | -259,650 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GRFS
GRIFOLS S A
|
Healthcare | 0.00% | 1.25% |
Sold All 😨
(Was: #24) |
0.3 | -2,500,000 | -100.0% |
CLOSED
|
— | $— | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IART
INTEGRA LIFESCI...
|
Healthcare | 0.00% | 1.04% |
Sold All 😨
(Was: #27) |
0.3 | -1,440,818 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
UNIQURE NV
|
Healthcare | 0.00% | 0.59% |
Sold All 😨
(Was: #41) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 0.00% | 0.54% |
Sold All 😨
(Was: #44) |
0.3 | -738,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.00% | 0.42% |
Sold All 😨
(Was: #50) |
0.3 | -935,909 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 0.00% | 0.38% |
Sold All 😨
(Was: #52) |
0.3 | -88,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ESTA
ESTABLISHMENT L...
|
Healthcare | 0.00% | 0.29% |
Sold All 😨
(Was: #58) |
0.3 | -139,512 | -100.0% |
CLOSED
|
— | $— | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ETON
ETON PHARMACEUT...
|
Healthcare | 0.00% | 0.22% |
Sold All 😨
(Was: #61) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CBLL
CERIBELL INC
|
Healthcare | 0.00% | 0.21% |
Sold All 😨
(Was: #62) |
0.3 | -360,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HROW
HARROW INC
|
Healthcare | 0.00% | 0.21% |
Sold All 😨
(Was: #63) |
0.3 | -85,498 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
AKERO THERAPEUT...
|
Healthcare | 0.00% | 0.17% |
Sold All 😨
(Was: #67) |
0.3 | -71,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 0.00% | 0.14% |
Sold All 😨
(Was: #68) |
0.3 | -100,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.00% | 0.12% |
Sold All 😨
(Was: #70) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 0.00% | 0.12% |
Sold All 😨
(Was: #71) |
0.3 | -80,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IOVA
IOVANCE BIOTHER...
|
Healthcare | 0.00% | 0.11% |
Sold All 😨
(Was: #73) |
0.3 | -976,707 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTGN
VISTAGEN THERAP...
|
Healthcare | 0.00% | 0.10% |
Sold All 😨
(Was: #75) |
0.3 | -550,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNKD
MANNKIND CORP
|
Healthcare | 0.00% | 0.08% |
Sold All 😨
(Was: #76) |
0.3 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMUX
IMMUNIC INC
|
Healthcare | 0.00% | 0.07% |
Sold All 😨
(Was: #77) |
0.3 | -1,580,007 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADVM
ADVERUM BIOTECH...
|
Healthcare | 0.00% | 0.07% |
Sold All 😨
(Was: #78) |
0.3 | -287,246 | -100.0% |
CLOSED
|
— | $— | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
LIQUIDIA CORPOR...
|
Healthcare | 0.00% | 0.06% |
Sold All 😨
(Was: #79) |
0.3 | -50,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EPIX
ESSA PHARMA INC
|
Unknown | 0.00% | 0.04% |
Sold All 😨
(Was: #80) |
0.3 | -4,362,026 | -100.0% |
CLOSED
|
— | $— | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MYO
MYOMO INC
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #81) |
0.3 | -704,275 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MREO
MEREO BIOPHARMA...
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #82) |
0.3 | -299,711 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TECX
TECTONIC THERAP...
|
Healthcare | 0.00% | 0.02% |
Sold All 😨
(Was: #83) |
0.3 | -25,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 120 holdings